COMMUNIQUÉS West-GlobeNewswire

Santé Canada autorise TAKHZYRO(MC) (lanadelumab en injection), le premier traitement à anticorps monoclonal en son genre destiné à la prévention de crises d’angioœdème héréditaire (AOH)

20/09/2018 - 13:00

Santé Canada autorise TAKHZYRO MC (lanadelumab en injection), le premier traitement à anticorps monoclonal en son genre destiné à la prévention de crises d’angioœdème héréditaire (AOH) Une nouvelle option de traitement [...]

Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

20/09/2018 - 13:00

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host [...]

RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference

20/09/2018 - 13:00

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]

Canada House Wellness Group Announces $25,000,000 Financing and Issuance of Stock Options

20/09/2018 - 13:00

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“ Canada House ” or the “ Company ”) is [...]

New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners

20/09/2018 - 12:30

Addressing aging population, TRU NIAGEN PRO now available for distribution by healthcare practitioners for patient health and wellness IRVINE, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an [...]

HEXO soutient le programme d’information sur le cannabis de la Société gastro-intestinale

20/09/2018 - 12:30

GATINEAU, Québec, 20 sept. 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO ) s’intéresse beaucoup à la responsabilité sociale d’entreprise (RSE) et à cet égard, elle examine attentivement l’ [...]

Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease

20/09/2018 - 12:30

Preparations for Biologics License Application (BLA) Filing Underway NEW YORK and MELBOURNE, Australia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong [...]

Digirad Corporation to Present at the Sidoti & Company Fall 2018 Conference on September 27, 2018

20/09/2018 - 12:00

SUWANEE, Ga., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ:DRAD), today announced that it will present at the Sidoti & Company Fall 2018 Conference on Thursday, September 27, 2018, at the New York [...]

Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders

20/09/2018 - 12:00

License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to [...]

Canopy Rivers Inc. Begins Trading on the TSX Venture Exchange

20/09/2018 - 12:00

TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (TSXV:RIV) (“ Canopy Rivers ” or the “ Company ”) is pleased to announce that effective at the opening of the market today, September 20, 2018, the Company’ [...]

BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology

20/09/2018 - 10:45

BEIJING, China and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Photocure ASA: Daniel Schneider appointed Chief Executive Officer

20/09/2018 - 08:30

Oslo, Norway, 20 September 2018: Photocure ASA (OSE: PHO), announces today that Daniel Schneider has been appointed President and Chief Executive Officer of Photocure. Mr Schneider joins Photocure from the position of [...]

Solon Eiendom ASA – Primary insider notification

20/09/2018 - 08:30

(Oslo, Norway, September 19, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 20.000 shares in Solon Eiendom ASA at a price of NOK 28.9831. Following [...]

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

20/09/2018 - 08:04

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients [...]

Nanobiotix : mise à jour des données de l’étude de Phase I/II dans les cancers de la tête et du cou et autres données présentées à ImmunoRad 2018

20/09/2018 - 08:04

Nanobiotix : mise à jour des données de l’étude de Phase I/II dans les cancers de la tête et du cou et autres données présentées à ImmunoRad 2018 Renforcement des données de NBTXR3 montrant l’impact potentiel de survie [...]

Shire plc: Rule 2.9 Announcement

20/09/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 September 2018 [...]

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

20/09/2018 - 08:00

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be [...]

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

20/09/2018 - 07:31

Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company ( formerly known as ThromboGenics ) focused on developing treatments for back of the eye diseases with an innovative [...]

ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

20/09/2018 - 07:30

LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating [...]